Status:
UNKNOWN
Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lead Sponsor:
PerCuro Clinical Research Ltd
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
19+ years
Brief Summary
This study was designed to gather data regarding the efficacy and safety of Rituxan in clinical practice whereby patients may present with concomitant medical conditions, medications as well as varyin...
Eligibility Criteria
Inclusion
- Subjects with active rheumatoid arthritis as defined by ACR criteria
- \> 18 years of age at time of consent
- Able to start RITUXAN therapy per the approved product monograph within approximately 30 days of confirmed enrollment
Exclusion
- Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins or to any component of RITXAN as per approved Product monograph
- Presence of any significant and or uncontrolled medical condition, which in the Investigator's opinion, precludes the use of RITUXAN as outlined in the Product Monograph
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00984711
Start Date
May 1 2007
End Date
December 1 2015
Last Update
September 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PerCuro Clinical Research Ltd.
Victoria, British Columbia, Canada, V8V 3P9